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The intestinal nematode Baylisascaris schroederi is an important cause of death for wild and captive giant pandas.
Inorganic pyrophosphatases (PPases) are critical for development and molting in nematode parasites and represent
potential targets for vaccination. Here, a new PPase homologue, Bsc-PYP-1, from B. schroederi was identified and
characterized, and its potential as a vaccine candidate was evaluated in a mouse challenge model. Sequence
alignment of PPases from nematode parasites and other organisms show that Bsc-PYP-1 is a nematode-specific
member of the family I soluble PPases. Immunohistochemistry revealed strong localization of native Bsc-PYP-1 to
the body wall, gut epithelium, ovary and uterus of adult female worms. Additionally, Bsc-PYP-1 homologues were
found in roundworms infecting humans (Ascaris lumbricoides), swine (Ascaris suum) and dogs (Toxocara canis). In
two vaccine trials, recombinant Bsc-PYP-1 (rBsc-PYP-1) formulated with Freund complete adjuvant induced
significantly high antigen-specific immunoglobulin (Ig)G but no IgE or IgM responses. Analysis of IgG-subclass
profiles revealed a greater increase of IgG1 than IgG2a. Splenocytes from rBsc-PYP-1/FCA-immunized mice secreted
low levels of T helper (Th)1-type cytokines, interferon-γ and interleukin (IL)-2, while producing significantly high
levels of IL-10 and significantly elevated levels of IL-4 (Th2 cytokines) after stimulation with rBsc-PYP-1 in vitro.
Finally, vaccinated mice had 69.02–71.15% reductions (in 2 experiments) in larval recovery 7 days post-challenge
(dpc) and 80% survival at 80 dpc. These results suggest that Th2-mediated immunity elicited by rBsc-PYP-1 provides
protection against B. schroederi, and the findings should contribute to further development of Bsc-PYP-1 as a
candidate vaccine against baylisascariasis.Introduction
Baylisascariasis is a neglected zoonotic helminthic dis-
ease caused by parasitic nematodes of the genus
Baylisascaris (Nematoda: Ascaridida) with great medical
and veterinary significance worldwide [1-3]. The causa-
tive pathogens, Baylisascaris spp., are widely distributed
in the giant panda (Ailuropoda melanoleuca), red panda
(Ailurus fulgens), raccoon (Procyon lotor), Ursid species
(Ursus maritimus, Ursus arctos pruinosus, Selenartos
thibetanus mupinensis and Ursus arctos lasiotus) and
other mammals including humans and can lead to se-
vere clinical visceral (VLM), ocular (OLM) and neural* Correspondence: guangyou1963@aliyun.com
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reproduction in any medium, provided the orlarva (NLM) migrans in these definitive or intermediate
hosts [4-7]. Among them, Baylisascaris schroederi is the
only endoparasite that appears to be consistently found
in the giant panda, a flagship species for wildlife conser-
vation in China, and represents a significant threat to
both wild and captive populations [8,9]. In nature, B.
schroederi infection rates among wild pandas may reach
between 50–100%, making it one of the leading causes
of death from primary and secondary infection in wild
populations [4,10,11]. Zhang et al. demonstrated that the
probability of death of wild pandas caused by this patho-
gen increased significantly between 1971 and 2005, and
the associated VLM was the most important cause of
death during the recent period 2001–2005 [8]. As with
all ascarid species, B. schroederi infection follows a
trophic pathway by ingestion with life cycle completion. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stage) usually inhabits the intestines of the giant panda,
while its migrating larvae may disseminate into various
body tissues. B. schroederi can induce extensive inflam-
mation and scarring of the intestinal wall and paren-
chyma of the liver and lung (mainly caused by larvae), as
well as intestinal obstruction, inflammation and even
death (caused by adults) in giant pandas [9,12-14]. Until
now the control of B. schroederi infection in pandas is
relied chiefly on chemotherapy, and treatment with
antiparasitic drugs requires multiple doses until the ani-
mal ceases to expel worms or shed eggs in feces [9].
However, alternative preventative and treatment strat-
egies are needed due to the rapid emergence of multi-
drug-resistant ascarids and pollution of the food chain
and the environment from chemotherapy, as well as the
persistent exposure of host animals to parasites of differ-
ent stages in their surroundings. Vaccines, particularly
target antigens that play crucial roles in the survival, de-
velopment and reproduction of parasitic nematodes
would be an ideal control strategy.
Inorganic pyrophosphatases (PPases, EC 3.6.1.1), a class
of cytosolic enzymes catalyzing the hydrolysis of inorganic
pyrophosphate (PPi) to ortho-phosphate (Pi), are widely
distributed among living cells and function in energy
metabolism, lipid metabolism and some biosynthetic reac-
tions [15]. PPases are essential for the growth and devel-
opment of prokaryotes, fungus, nematodes and plants
(e.g., tobacco and potato) [16-22]. For parasites, such as
Ascaris roundworms, PPases are believed to be further in-
volved in molting, as indicated in Ascaris suum by RNA-
mediated interference and enzyme activity inhibition as-
says [23,24]. Considering the important roles of PPases in
life processes of various organisms including parasitic
nematodes, some of these enzymes have been selectively
targeted for pharmaceutical and vaccine purposes [25].
For example, an adjuvanted recombinant PPase antigen
from ascarids was recently demonstrated to induce a high
level of protection (>70%) against A. suum challenge in
mice, and its potential for use as a candidate vaccine
against ascariasis is further suggested in pigs [23]. How-
ever, no information on PPases of B. schroederi is available
to date. More importantly, B. schroederi-specific protein
antigens as potential targets for vaccines and/or chemo-
therapeutic agents are still scarce with only three anti-
gen molecules (Bs-Ag1, Bs-Ag2 and Bs-Ag3) available
[12,13,26], and the precise mechanism of protective
immunity against B. schroederi infection has not been
determined, although preliminary results have been
published on other gastrointestinal parasitic infections
showing induction of strong T helper (Th) 2-biased re-
sponses in various experimental animal models [27-30].
Therefore, the aims of the present study were (i) to clone
and express a new PPase, Bsc-PYP-1, from B. schroederi;(ii) to investigate the localization of this native protein in
adult parasites and its expression profiles at various devel-
opmental stages of B. schroederi, including embryonated
eggs, 2nd and 3rd-stage larvae (L2-L3) and adults; (iii) to
test the immunogenicity and protective potential of re-
combinant Bsc-PYP-1 (rBsc-PYP-1) following vaccination
with Freund complete adjuvant (FCA) in challenged mice;
and finally (iv) to determine the T helper (Th)1 and/or
Th2 immune profile induced by vaccination with this re-
combinant protein based on levels of serum immuno-
globulin (Ig)G, its subclasses (IgG1 and IgG2a) and
cytokines (e.g., interleukin (IL)-2, IL-4, IL-10 and inter-
feron (IFN)-γ). To our knowledge, this is the first report
that evaluates the protective efficacy and corresponding
immune mechanisms of the rBsc-PYP-1 protein as a vac-
cine in a mouse challenge model. The results will contrib-
ute to improve our understanding of Bsc-PYP-1 as a
candidate vaccine against baylisascariasis.
Materials and methods
Parasites
B. schroederi female adults derived from naturally
infected giant pandas were provided by the Depart-
ment of Parasitology, College of Veterinary Medicine,
Sichuan Agricultural University (Ya’an, China). Unem-
bryonated and embryonated eggs were obtained es-
sentially as described elsewhere [31]. B. schroederi
infective L2 from embryonated eggs and liver-stage L3
from infected mice were collected as previously de-
scribed [32]. Adult Ascaris lumbricoides worms were
obtained from patients after treatment with piperazine
in Jianyang, Sichuan Province of China. Adult A. suum
and adult Toxocara canis were isolated from infected
pigs at a local slaughterhouse in Ya’an and an infected
dog in Chengdu, China, respectively. Protein con-
centrations of phosphate-buffered saline (PBS)-soluble
parasite antigens were measured using the micro-
bicinchoninic acid (BCA) protein assay kit (Pierce/
Thermo Fisher Scientific, Asheville, NC, USA).
Animals
Six- to eight-week-old female specific-pathogen-free (SPF)
BALB/c mice were purchased from the Laboratory Animal
Center of Sichuan University (Chengdu, China). New
Zealand white rabbits were obtained from the Laboratory
Animal Center of Sichuan Agricultural University. All ani-
mals were housed under a barrier environment in sterile
cages in the laboratory animal house of the National Insti-
tute of Animal Health (NIAH) and were fed pelleted food
and sterilized water ad libitum. Animals were acclimated
to these conditions for 1 week prior to the experiment.
Institutional Ethical and Animal Care guidelines were
followed during the sampling exercise, and all procedures
were reviewed and approved by the Institute of Animal
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Amplification and bioinformatic analysis of Bsc-PYP-1
coding sequence
Total RNA isolation from female adults of B. schroederi
and the first-strand cDNA synthesis were performed
according to standard protocols [12]. The resulting cDNA
was used as the template for PCR amplification with a
sense primer (5′-TAAAGATGGCATTGGCCGCATCG-
3′) and an antisense primer (5′-CACTCTTTGATGAAA
TGCCATCTGTCA-3′) designed to target the A. suum
AdR44 cDNA sequence (GenBank accession: AB091401).
The PCR amplified product was gel-purified, cloned into
the pMD19-T vector (TaKaRa, China) and sequenced. An
Open Reading Frame Finder [33] and the Lasergene soft-
ware package for Windows (DNASTAR, Madison, WI,
USA) were used to analyze the open reading frame (ORF)
of the nucleotide sequence and deduce the amino acid se-
quences. Similarity comparisons with previously reported
sequences in GenBank were performed using DNAMAN
version 3.0 (Lynnon Biosoft, Quebec, Canada) and on-line
Blast tools at the National Center for Biotechnology Infor-
mation (NCBI) website [34]. Based on their similarities,
multiple sequence alignment and phylogenetic analysis
were obtained. Sequences were aligned with ClustalW2
[35], and the phylogenetic tree was constructed by the
neighbor-joining (NJ) method [36] and plotted with MEGA
3.1 [37]. In addition, the molecular weight (MW) and iso-
electric point (pI) of Bsc-PYP-1 were calculated using
ProtParam [38], and the signal sequence was predicted with
the SignalP 3.0 server [39].
Expression and purification of recombinant Bsc-PYP-1
fusion protein
A partial coding region of Bsc-PYP-1 cDNA, except for
the predicted signal peptide, was amplified by PCR using a
sense primer (5′-CCCAAGCTTCGACAATCTCGCAGT-
3′) containing a HindIII site (italics) and an antisense pri-
mer (5′-CCGCTCGAGTCACTCTTTGATGAAATGCCA
TCTGTC-3′) containing an XhoI site (italics). The PCR
products were digested with HindIII and XhoI (TaKaRa),
gel-purified and ligated into the plasmid expression vector
pET32a (+) (Novagen, Madison, WI, USA). The resulting
plasmid with a correct Bsc-PYP-1 insert was transformed
into E. coli BL21 (DE3) cells (Invitrogen, Carlsbad, CA,
USA) and subsequently grown at 37 °C to an OD600 of 0.6
in Luria-Bertani (LB) broth supplemented with 50 μg/mL
ampicillin. The transformed cells were induced by adding
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for
5 h at 37 °C. The cells were harvested and resuspended in
lysis buffer [50 mM NaH2PO4 (pH 8.0), 10 mM Tris–HCl
(pH 8.0), 100 mM NaCl]. The samples were then soni-
cated until they were no longer viscous. Cell lysates andinclusion bodies were pelleted by centrifugation at
25 000 × g for 15 min at 4 °C. The pellets were resus-
pended in lysis buffer plus 8 M urea and incubated on
ice for 1–2 h to completely solubilize the protein. His6-
tagged rBsc-PYP-1 proteins were expressed in an inclu-
sion body form and purified by Ni2+ affinity chromatog-
raphy using a 10 mL His-Bind Resin column (Novagen)
under denaturing conditions as described in the manu-
facturer’s protocol. Proteins eluted with imidazole were
concentrated with Amicon Ultra Centrifugal Filter
Devices (Millipore, Billerica, MA) and then dialyzed
against PBS, containing decreasing concentrations of
urea (8, 6, 4, 3, 2, and 1 M, and PBS only). Thereafter,
concentrations of purified proteins were measured with
the micro-BCA protein assay reagent (Pierce/Thermo
Fisher Scientific), and the potential endotoxin contam-
ination was accessed using the limulus amoebocyte
lysate-based gel-clot assay as described elsewhere [40].
Sera
Rabbit immune serum against B. schroederi was obtained
as previously described [12]. To obtain mouse polyclonal
sera against rBsc-PYP-1, 10 female BALB/c mice were
immunized with a subcutaneous injection of 50 μg of
rBsc-PYP-1 purified as described above and mixed with
FCA (Sigma, St. Louis, USA), followed by 2 booster im-
munizations (2 weeks apart) using the same route and
dose in the same adjuvant. Mice were bled 2 weeks after
the second booster immunization. The antisera from the
mice were mixed and stored at −20 °C until use.
Immunoblot and immunohistochemical analyses
For immunoblot analysis, parasite antigens or rBsc-PYP-
1 proteins were lysed in an electrophoresis sample
buffer, run on 10% SDS-PAGE, transferred onto nitro-
cellulose membranes and blocked with 5% skim milk
in Tris-buffered saline (TBS) buffer for 1 h. Parasite-
derived Bsc-PYP-1 was detected by incubation of the
membranes with the mouse anti-rBsc-PYP-1 serum. To
determine the antigenicity of rBsc-PYP-1, rabbit or
mouse sera from animals repeatedly inoculated with B.
schroederi embryonated infective eggs, anti-rBsc-PYP-1
mice serum and naïve rabbit or mouse sera were used.
After three washes with TBS-Tween 20 (TBST), the
membranes were further incubated for 2 h with 1:200 di-
luted alkaline phosphatase-conjugated goat anti-mouse
or anti-rabbit IgG (ICN Pharmaceuticals, Costa Mesa,
CA). Protein signals were visualized using nitroblue
tetrazolium and 5-bromo-4-chloro-3-in-dolylphosphate
(NBT/BCIP; USB, Cleveland, OH). For immunohisto-
chemical analysis, adult female B. schroederi sections
were probed with specific anti-rBsc-PYP-1 mouse serum
(1:100), followed by a peroxidase-labeled anti-mouse IgG
goat antibody (Biosynthesis Biotechnology Co., Ltd., Beijing,
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light microscope (Nikon Optiphot II, Nikon, Japan).
Immunization and challenge
For immunization, rBsc-PYP-1 proteins were suspended
in PBS (0.01 M, pH 7.4) at a concentration of 600 μg/mL
and mixed with an equal volume of FCA (Sigma) as de-
scribed previously [13]. Control FCA mixed with PBS and
control PBS were also used for challenge studies. In the
first trial, 90 mice were randomly assigned into three
groups (30 animals per group) and injected subcutane-
ously with the rBsc-PYP-1 suspension, FCA mixed with
PBS or PBS alone (100 μL per animal). First and second
booster injections were prepared in the same manner and
administered at the same dose at 14-day intervals. Two
weeks after the final injection, 10 mice from each group
were sacrificed, and the spleens were removed aseptically
for cytokine assays. The remaining 20 animals in each
group were inoculated orally with 3200 B. schroederi in-
fective embryonated eggs. Ten out of twenty mice chal-
lenged with B. schroederi from each group were sacrificed
and dissected at one week post-challenge (wpc). After
histopathological examination, lungs and livers were re-
moved from the animals and minced with a surgical knife,
and larvae were recovered by the Baermann method as
described by Slotved et al. [41] and counted under a light
microscope (Nikon). For the last 10 remaining mice in
each group, mortality was monitored over a period of
80 days after the challenge, and relative percent of survival
(RPS) was calculated as follows: RPS = {1 − (% mortality
in immunized mice / % mortality in control mice)} × 100,
as described elsewhere [42].
In order to further assess the potential efficacy of rBsc-
PYP-1 as a new vaccine candidate against B. schroederi,
the vaccination trial with mice was repeated in trial II
essentially as described in trial I, with the exception that
the challenge occurred 1 week after the final booster im-
munization. The overall experimental design is summa-
rized in Table 1. Serum samples in both trials were
collected from the tail vein after each immunization and
at 42, 49, 63, 77, 84 and 91 days post-vaccination (dpv) for
antibody assays and for analysis of the kinetics of humoral
immune response throughout the challenge as previously
described [12,13,26,43].
Antibody assays
Measurements of Bsc-PYP-1-specific serum IgM, IgE,
IgG, and IgG-subclass (e.g., IgG1 and IgG2a) antibodies
in immunized mice derived from trials I and II were
performed using enzyme-linked immunosorbent assays
(ELISA). The IgM, IgG and IgG subclass antibody levels
were determined with horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgM, IgG and IgG subclass
antibodies (Bethyl Laboratories, Montgomery, TX, USA).Affinity purified goat anti-mouse IgM, IgG, IgG1 and
IgG2a (Bethyl Laboratories) were used as standards. For
rBsc-PYP-1-specific IgE measurements, anti-mouse IgE
was used as the capture antibody, and IgE was quantified
by using biotinylated anti-mouse IgE (Bethyl Laboratories)
coupled with the standard produced from rat monoclonal
anti-mouse IgE antibody (diluted 1:10 000) (American Re-
search Products, Belmont, MS, USA) as described else-
where [23,44].
ELISA were performed in polystyrene 96-well micro-
titer plates (Invitrogen) using 100 μL reaction mixtures
with rBsc-PYP-1 antigen coated at a concentration of
2 μg/mL in 0.1 M carbonate buffer (pH 9.6) as described
previously [13]. The plates were washed after incubation
of the plates at 4 °C for 14–16 h (and after each subse-
quent incubation) three times with PBS containing 0.05%
Tween 20 (PBS-T). Wells were blocked with 100 μL of
PBS-2% bovine serum albumin (BSA) (Sigma) for 2 h at
37 °C, and then incubated with serial two-fold dilutions
(100 μL) of test serum samples at 37 °C for 1 h. HRP-
conjugated goat anti-mouse IgM (diluted 1:5000), IgG
(diluted 1:500) or IgG subclass (diluted 1:5000) anti-
bodies and HRP-conjugated goat anti-rat IgG (diluted
1:1000) (Bethyl Laboratories) antibody were added to
the wells in 100 μL for a further incubation at 37 °C for
1 h. Both test sera and conjugates were diluted in PBS.
Antibody binding was detected at 37 °C with 100 μL of
o-phenylenediamine dihydrochloride (OPD; Sigma)
substrate (0.4 mg/mL OPD, 50 mM dibasic sodium
phosphate, 25 mM citric acid and 30% H2O2), and the
color reaction was terminated with 100 μL of 2 M
H2SO4. The results were obtained with a microplate
reader (Dynatech MR500, Deckendorf, Germany), and
the endpoint titer was defined as the highest dilution of
serum at which the optical density at 490 nm (OD490)
was at least above the doubled blank control (OD490
0.15). Negative and blank controls were included on
each plate. Antibody concentrations were calculated
using a standard curve generated with reference sera
(Bethyl Laboratories).
Spleen cell culture and cytokine assays
Spleen cell suspensions were prepared essentially as
described previously [23,45]. After isolation, splenic
cells (4 × 106) were subsequently cultured at 37 °C and
5% CO2 in 24-well plates in a final volume of 1.0 mL/
well. The cells were stimulated with rBsc-PYP-1 anti-
gen (15 μg/mL) for 72 h, and culture supernatants were
collected and stored at −80 °C for subsequent cytokine
analysis using a commercially available mouse Ad Lit-
teram ELISA Kit with pre-coated plates (ADL, San Diego,
CA, USA) for IL-2, IL-4, IL-10 and IFN-γ. Cytokine
concentrations were calculated against standard curves
constructed with supernatants containing known amounts




0, 2, 4 wpv b 6-wpv b 1-wpc c 1-11 wpc c (80-dpc)
Vaccination Cytokine assay Challenge Larval recovery Mortality
(Trial I) (3 times per group) (No. a) (No. a, d) (No. a) (No. a)
rBsc-PYP-1/FCA/PBS 30 rBsc-PYP-1 (FCA plus PBS) 10 20 10 10
FCA/PBS 30 FCA plus PBS 10 20 10 10




0, 2, 4 wpv b 5-wpv b 6-wpv b 1-wpc c 1-12 wpc c (80-dpc)
Vaccination Challenge Cytokine assay Larval recovery Mortality
(Trial II) (3 times per group) (No. a ) (No. a, e) (No. a, f) (No. a)
rBsc-PYP-1/FCA/PBS 30 rBsc-PYP-1 (FCA plus PBS) 20 10 10 -
FCA/PBS 30 FCA plus PBS 20 10 10 -
PBS 30 PBS 20 10 10 -
a Number of mice involved in this assay.
b Week(s) post-vaccination.
c Week(s) post-challenge.
d Number of remaining mice in each experimental group after “Cytokine assay” and used for the subsequent determinations of “Larval recovery” and “Mortality”.
e Number of remaining mice in each experimental group after “Challenge”.
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standards and samples were run in triplicate.
Statistical analysis
The data were expressed as the means ± standard
deviations (SD). Comparisons between experimental
groups were performed by one-way ANOVA, LSD,
Duncan’s test or Scheffe’s test using SPSS13.0 Data
Editor (SPSS Inc., Chicago, IL, USA). P values < 0.05
were considered to be significant. All experiments were
carried out a minimum of two times with 10 mice per
group. Percent reduction was calculated as follows: %
reduction = [(average number of larvae recovered from
control mice − average number of larvae recovered
from immunized mice)/average number of larvae re-
covered from control mice] × 100, as previously de-
scribed [12]. In addition, the nucleotide sequence
determined in the present study has been deposited in
the DDBJ/EMBL/GenBank database under accession
number GQ859591.
Results
Molecular cloning and identification of Bsc-PYP-1
The cDNA encoding Bsc-PYP-1 with a length of 1,088 bp
was obtained by PCR amplification using specific oligonu-
cleotides designed based on the A. suum DNA sequence
(GenBank ID: AB091401.1). Sequence analysis shows that
the cloned cDNA contained a single ORF of 1,083 bpFigure 1 Sequence alignment and phylogenetic analysis of Bsc-PYP-1
acid sequence of Bsc-PYP-1 with those of homologous PPases from other s
protein sequence database (accession numbers are indicated in parenthese
A. suum (BAC66617), B. malayi (EDP36300), L. loa (EFO25093), C. elegans (NP
spiralis (EFV52164). Regions of identity (*), strong similarity (:) and weak sim
better alignment. The putative PPase signature motif is enclosed in the bo
marked with black stars. The predicted signal peptide is underlined. Percen
the end of each sequence. (B) Phylogenetic analysis of the full-length amin
nematodes mentioned in (A). The tree was constructed by the NJ method
nodes (1000 replications). The scale indicates an estimate of substitutions pcoding for a putative protein of 360 amino acids with a
predicted molecular mass of 40.507 kDa and pI of 6.32.
The first 20 amino acids corresponded to a signal peptide
(Figure 1A). Removal of the signal peptide would result in
a mature protein with a molecular mass of 38.478 kDa
and a pI of 6.31. Six different clones were sequenced, and
no differences were found at the amino acid level.
A homology search for the protein performed using
information obtained from NCBI revealed that Bsc-
PYP-1 shared the highest amino acid sequence similar-
ity with a PPase protein (AdR44) from A. suum (95.8%)
(GenBank accession: BAC66617), followed by 64.4%
similarity with Cre-PYP-1 protein from Caenorhabditis
remanei (GenBank accession: EFP04160), and 45.8–
56.5% similarity with putative PPases from parasitic nema-
todes (Brugia malayi (GenBank accession: EDP36300),
Loa loa (GenBank accession: EFO25093) and Trichinella
spiralis (GenBank accession: EFV52164)) and free-living
nematodes (Caenorhabditis elegans (GenBank accession:
NP_001023073) and Caenorhabditis briggsae (GenBank
accession: XP_002633752)) (Figure 1A). Sequence simi-
larities were found throughout the protein but less fre-
quently at both ends. Moreover, a PPase signature
sequence (DNDPID) and 13 functionally important and
evolutionarily well-conserved active site residues (E:125,
K:133, E:135, R:155, Y:170, D:192, D:194, D:197, D:224,
D:229, K:231, Y:269 and K:270; in Bsc-PYP-1) in family I
soluble PPases were also observed in the sequence analysiswith homologous PPases. (A) Alignment of the deduced amino
pecies. The following sequences were retrieved from the GenBank
s) and aligned using the ClustalW2 program: B. schroederi (GQ859591),
_001023073), C. briggsae (XP_002633752), C. remanei (EFP04160) and T.
ilarity (.) are indicated. Gaps, marked by hyphens, are introduced for
x, and 13 well-conserved residues in all family I soluble PPases are
tages of sequence similarity with respect to Bsc-PYP-1 are shown at
o acid sequences of Bsc-PYP-1 and homologous PPases from the eight
and plotted with MEGA 3.1. Bootstrap values are indicated at the
er site, using the optimized model setting.
Figure 2 SDS-PAGE and Western blotting analysis of purified
rBcs-PYP-1. M, molecular mass marker in kDa; lane 1, purified rBcs-
PYP-1 after dialysis; lanes 2–5: purified rBsc-PYP-1 was probed with
rabbit immune serum against B. schroederi (experimental group, lane
2), naive rabbit serum (negative control, lane 3), anti-rBsc-PYP-1
mouse serum (positive control, lane 4) and pre-immune mouse
serum (negative control, lane 5), respectively. Two micrograms of
protein was loaded in each lane of an SDS-10% polyacrylamide gel,
subjected to electrophoresis and blotted onto nitrocellulose
membranes. The protein was stained with Coomassie Blue R250 in
the gel (lane 1), while the protein bound to serum samples was
detected using NBT/BCIP in the Western blot (lanes 2–5). The arrow
indicates the location of rBsc-PYP-1-specific bands.
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vation of functionally relevant residues with these other
protein members of the PPase superfamily, Bsc-PYP-1 was
determined to be a family I soluble PPase.
Relationships of the eight nematodes mentioned above,
based on the full-length amino acid sequence alignment of
the corresponding PPase proteins, were further deter-
mined by phylogenic analysis (NJ tree) (Figure 1B). The
results were in good agreement with traditional taxonomy,
with B. schroederi and A. suum clustering into a group
within the order Ascaridida, B. malayi and L. loa cluster-
ing into another group within the order Spirurata, and C.
remanei, C. elegans and C. briggsae grouping into a branch
belonging to the order Rhabditata (Figure 1B).
Expression, purification and biochemical analysis of
rBsc-PYP-1
The cDNA fragment encoding mature Bsc-PYP-1 was suc-
cessfully sub-cloned into the pET32a (+) prokaryotic
expression vector (Invitrogen), and the recombinant pro-
tein was overexpressed in E. coli BL21 (DE3) Star cells as a
single His6-tagged fusion protein with an expected size
of ~58 kDa (data not shown). Since the epitope tag fusion
peptide in rBsc-PYP-1 was ~20 kDa in size, rBsc-PYP-1
therefore had an approximate molecular mass of 38 kDa,
similar to that predicted from the amino acid sequence of
Bsc-PYP-1. After induction for 5 h with IPTG, the
transformed bacterial cells expressing peak amounts of
rBsc-PYP-1 were sonicated. rBsc-PYP-1 found mostly in in-
clusion bodies were made soluble by extraction with 8 M
urea (not shown). After purification by affinity chromatog-
raphy using His binding columns under denaturing condi-
tions, the rBsc-PYP-1 proteins were subsequently refolded
by dialysis against PBS containing successively decreasing
concentrations of urea. The yield of rBsc-PYP-1 was ap-
proximately 4 mg/L of bacterial culture. The purity of the
preparation was accessed by SDS-PAGE (Figure 2, lane 1)
and further characterized by Western blotting using rabbit
immune serum against B. schroederi (experimental group),
anti-rBsc-PYP-1 mouse serum (positive control), or naïve
rabbit and mouse sera (negative controls). A positive band
of 58 kDa was observed in the experimental group and
positive control, in contrast with the two negative controls,
suggesting that rBsc-PYP-1 had good antigenicity (Figure 2,
lanes 2–5). The purified rBsc-PYP-1 protein was then used
for the production of polyclonal antibodies in mice, immu-
nohistochemical analysis and the examination of immuno-
reactivity with various immune sera, as well as for vaccine
experiments using the B. schroederi infection mouse model.
Identification of the native Bsc-PYP-1 antigen in B.
schroederi and homologues in other ascarids
The native Bsc-PYP-1 antigen was identified at various
stages of development in B. schroederi. Expression ofBsc-PYP-1 from parasites was evaluated by immunoblot
analysis using extracts prepared from embryonated eggs,
L2, liver-stage L3 and female adult worms. Anti-rBsc-
PYP-1 mouse serum reacted strongly with a 38-kDa
parasite-derived antigen from extracts of all B. schroederi
life-cycle stages (Figure 3A). By contrast, sera from pre-
immune mice did not react with any antigens in the
parasite extract (not shown). These findings revealed
that the endogenous Bsc-PYP-1 protein was commonly
expressed in B. schroederi at all developmental stages.
Additionally, we also performed immunoblot analysis
of human (A. lumbricoides), swine (A. suum) and dog
(T. canis) roundworms using anti-rBsc-PYP-1 mouse
serum. The mouse serum immunoreacted with a 38-kDa
PBS-soluble protein from A. lumbricoides, the same size
as that of parasite-derived Bsc-PYP-1. Interestingly,
38-kDa immunoreactive bands were also observed in
PBS-soluble extracts from A. suum and T. canis with
nearly equal intensities as parasite-derived Bsc-PYP-1
observed in A. lumbricoides, indicating the presence of a
Figure 3 Identification of endogenous Bsc-PYP-1 from B.
schroederi and homologues from other ascarids. (A) Identification
of endogenous Bsc-PYP-1 at various developmental stages of B.
schroederi. Parasite extracts were prepared essentially as described in
Materials and Methods. Eighty micrograms of each parasite extract was
separated by SDS-PAGE (10%), and the proteins were then blotted
onto a nitrocellulose membrane. Endogenous Bsc-PYP-1 proteins
bound to mouse anti-rBsc-PYP-1 serum were detected by NBT/BCIP.
Lane 1, rBsc-PYP-1 (5 μg); lane 2, female adult worms; lane 3, liver-stage
L3; lane 4, L2; lane 5, embryonated eggs. (B) Expression of Bsc-PYP-1
homologues in ascarid roundworms. Sixty micrograms of protein
equivalents of each adult parasite extract were subjected to SDS-PAGE
(10%) and then blotted onto a nitrocellulose membrane. Bsc-PYP-1
homologues bound to the anti-serum were detected as mentioned
above. Lane 1, rBsc-PYP-1 (5 μg); lane 2, A. lumbricoides; lane 3, B.
schroederi; lane 4, A. suum; lane 5, T. canis.
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worms (Figure 3B). Sera from mice prior to immunization
did not react with any of the antigens present in the para-
site extracts (data not shown).
Immunohistochemical localization of endogenous Bsc-
PYP-1 in adult female B. schroederi worms
The localization of endogenous Bsc-PYP-1 protein was
determined by immunohistochemistry using anti-rBsc-
PYP-1 mouse serum and naïve mouse serum. Specific
staining was clearly observed in sections probed with
Bsc-PYP-1-specific serum but not in those probed
with normal mouse serum (Figures 4A-D). The results
show that endogenous Bsc-PYP-1 proteins were lo-
calized in various tissues, such as the hypodermis,
dorsal and lateral hypodermal chord, muscle tissues,
gut epithelium, non-embryonated eggs within the
uterus, uterus and ovary of a female adult B. schroderi
(Figures 4A and 4C). Moreover, the ubiquitous pres-
ence of Bsc-PYP-1 homologous proteins in various or-
gans of ascarids from humans and swine was also
detected (data not shown), consistent with observa-
tions from previous studies [19].Reactivity of rBsc-PYP-1 with various immune sera
The immunoreactivity of rBsc-PYP-1 with sera from rab-
bits and mice repeatedly inoculated with B. schroderi in-
fective embryonated eggs was examined by immunoblot
analysis. Both sera reacted with the rBsc-PYP-1 band
with equal intensities, further demonstrating the good
antigenicity and immunogenicity of the recombinant pro-
tein (Figure 2 and data not shown). Meanwhile, rabbit and
mouse pre-immune sera did not react with rBsc-PYP-1.
Immunoprotective effect of rBsc-PYP-1 as a recombinant
protein vaccine against B. schroederi
Efficacy of the rBsc-PYP-1 protein vaccine against B.
schreoderi migratory-phase infection was investigated in
BALB/c mice receiving one primary vaccination and two
boosters, followed by an oral challenge with 3200 B.
schreoderi infective embryonated eggs, based on two inde-
pendent trials (trials I and II) performed under the same
conditions, with the exception of different challenge
timepoints, as summarized in Table 1. In trial I, at one
wpc, mice vaccinated with rBsc-PYP-1/FCA had a signifi-
cantly (P = 0.024) reduced number of B. schreoderi liver-
stage L3 recovered from the liver and a further significant
(P = 0.0085) reduction in recovered larvae from lungs
compared with either mice vaccinated with PBS plus FCA
or PBS alone, giving a total reduction of 69.02% in the
number of recovered larvae from immunized mice com-
pared with the controls (P < 0.001) (Figure 5). No signifi-
cant differences were observed between the two control
groups. In trial II, a significant larvae reduction (including
in the livers and lungs) was also shown in the group vacci-
nated with rBsc-PYP-1/FCA (71.15%, P < 0.001) (Figure 5).
The reduction of parasitic load in trial II was 2.13% greater
than that in trial I, but this difference was not statistically
significant (P > 0.05). Moreover, in both trials, histopatho-
logical observations of livers and lungs removed from vac-
cinated mice or non-vaccinated mice show that the
occurrence of typical verminous interstitial hepatitis (“milk
spotted liver”) or verminous pneumonia (pulmonary
hemorrhage) following challenge infections was notably
reduced in the vaccinated group, compared with the con-
trol groups (data not shown).
To further test whether immunization with rBsc-PYP-
1 could also arrest larval development and decrease the
risk of death caused by visceral larval migrans, the 10
remaining mice in each group in trial I were monitored
for survival. No mortality was observed among all ex-
perimental groups until 8 wpc. Thereafter, the cumula-
tive mortalities of the mice vaccinated with adjuvanted
rBsc-PYP-1, PBS plus adjuvant and PBS alone were 20%,
100% and 100%, respectively, which corresponded to a
relative percent of survival of 80% for rBsc-PYP-1-vaccinated
mice compared with the controls (Figure 6). At 80 days after
challenge, all surviving mice were sacrificed. B. schreoderi
Figure 5 Numbers of B. schroederi larvae recovered from livers, lungs or both in mice vaccinated with rBsc-PYP-1 coupled with FCA.
Mice were vaccinated three times subcutaneously and then inoculated orally with 3200 B. schroederi infective embryonated eggs at 1 week (trial
II) or 2 weeks (trial I) after the final vaccination, as described in Materials and Methods. Mice were sacrificed at 1 wpc, and the migrating larvae
were recovered from livers or lungs. The results are expressed as the mean ± SD in each group of 10 mice. Asterisks indicate that the mean value
was significantly lower than that of the group vaccinated with PBS plus FCA or PBS alone (*P < 0.05, **P < 0.01, ***P < 0.001). NS denotes no
statistically significant difference, and the error bars indicate SD.
Figure 4 Immunohistochemical localization of endogenous Bsc-PYP-1 in B. schroederi female adult worms. Worms were fixed in
paraformaldehyde and embedded in paraffin as described in Materials and Methods. The sections (6-μm thickness) were incubated with either
mouse anti-rBsc-PYP-1 serum at 1:100 (A) or pre-immune serum at 1:100 (B) diluted in PBS. (C) and (D) (both 20×) are magnified areas of (A) and
(B) (both 10×), respectively. Arrows indicate antibody-labeled regions. Abbreviations: Mu, muscle; Cu, cuticle; Lc, lateral chord; Hd, hypodermis; Ov,
ovary; Gu, gut; Gue, gut epithelium; Ut, uterus; Nee, non-embryonated eggs.
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Figure 6 RPS rates in immunized mice. Mice were immunized
three times with rBsc-PYP-1/FCA/PBS (O), FCA/PBS () or PBS (),
followed by oral challenge with 3200 B. schroederi infective
embryonated eggs at 2 weeks after the last immunization in trial I.
Each group consisted of 10 mice. All mice were monitored for
mortality for 80 days after the challenge, and the mortality rates
(right side) corresponding to RPS rates (left side) are shown.
Statistically significant differences (P < 0.05) are indicated
by asterisks.
Figure 7 Serum IgG and IgG subclass (IgG1 and IgG2a) responses ind
subclasses before and after challenge with B. schroederi infective embryonated
subcutaneously vaccinated three times with rBsc-PYP-1 mixed with FCA in PB
after each vaccination and at 0 (challenge or 6 wpv), 1, 3, 5, 6 and 7 wpc. End
from immunized and control mice were determined by ELISA. Values are exp
(V1, V2, and V3) and challenge (C) are marked with black arrows, and asterisks
PYP-1/FCA/PBS vaccination group and two control groups (PBS plus FCA or P
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lung, kidney, brain, spleen and muscle tissues of moribund
and sacrificed mice during this period, suggesting that
mortality was caused by B. schreoderi infection.
Serum antibody responses to vaccination in trials I and II
To evaluate the potential of rBsc-PYP-1 to induce host-
protective antibodies, levels of rBsc-PYP-1-specific total
IgG, IgE, IgM and IgG-subclasses (including IgG1 and
IgG2a) antibodies in vaccinated mice sera derived from
trials I and II were measured at various times (0, 2, 4, 6,
7, 9, 11, 12, 13 wpv). As shown in Figure 7A, the amount
of rBsc-PYP-1-specific IgG in mice vaccinated with rBsc-
PYP-1/FCA within trial I significantly (P < 0.001) in-
creased after the first immunization and remained at a
high level until the end of the study period, i.e. 91 days,
compared with either the adjuvant control or blank con-
trol. Interestingly, two peaks of rBsc-PYP-1-specific IgGuced by rBsc-PYP-1 in mice. Mice were tested for serum IgG and its
eggs either at 5 wpv (trial II) or at 6 wpv (trial I). Mice were
S at 14-day intervals, and serum samples were collected from the tail vein
point titers of anti-rBsc-PYP-1 IgG (A) and IgG-subclass (B) antibodies
ressed as the mean ± SD for each group of six mice. Vaccination times
in A and B indicate statistically significant differences between the rBsc-
BS alone) (P < 0.001). Error bars represent SD.
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wpv and another at 5 wpc (Figure 7A). No detectable
antigen-specific IgE response was observed in these mice
sera even after the first and second booster vaccinations
(data not shown). A similar pattern of antibody induc-
tion was also seen for rBsc-PYP-1-specific IgM, although
the amount increased only slightly at 1 wpc and lasted
2 weeks at a low level. Interestingly, no significant differ-
ence in the rBsc-PYP-1-specific IgM level was found
compared with the controls (not shown). To further
evaluate the type of immune response (Th1 or Th2) in-
duced by rBsc-PYP-1 in vivo, IgG subclasses were also
measured. Both IgG1 and IgG2a levels were significantly
(all P values < 0.001) increased at 2, 4 and 6 wpv com-
pared with the two controls (PBS plus adjuvant and PBS
alone), but vaccination with rBsc-PYP-1 induced a more
clear pattern of IgG1 response (Figure 7B).
In trial II, compared with the controls, a significant
IgG response was also detected in the group immunized
with rBsc-PYP-1/FCA (P < 0.001) (Figure 7A); however,
due to the challenge timepoint being earlier than that
in trial I, the level of rBsc-PYP-1-specific IgG in immu-
nized mice seemed to decline after 4 wpv to lower levels
than those in trial I until the end of the study, with the
exception of the 3 and 7 wpc timepoints. Similar anti-
body changes were also observed in the IgG1 and IgG2a
subclasses (see Figure 7B). No significant differences in
the trend or level of antigen-specific IgE and IgM re-
sponses were found in trial II when compared with those
in trial I (data not shown). Additionally, as seen in Figure 7,
the IgG, IgG1 or IgG2a titers in the two controls of these
two trials, appeared to slightly increase after mice were
challenged with B. schreoderi infective embryonated eggs,
although statistically significant differences were still
observed between them and the vaccination group. In
contrast, no significant responses were noted prior to ex-
posure to this parasite.
Cytokine responses in stimulated splenocyte culture
supernatants
Cytokine secretion in rBsc-PYP-1-stimulated splenocyte
culture supernatants was quantified by ELISA in trial I
and further confirmed in trial II. In trial I, in vitro-stim-
ulated splenic T cells from mice vaccinated with rBsc-
PYP-1/FCA secreted a significantly higher level of IL-10
(P < 0.001) and a significantly increased level of IL-4
(P < 0.01) (Th2-type cytokines), compared with the
levels in stimulated T cells from two non-vaccinated
controls (FCA mixed with PBS and PBS alone) (Figure 8).
However, stimulated T cells from immunized mice re-
leased slight but nonsignificant increases of both IFN-γ
and IL-2 (Th1-type cytokines) levels (P > 0.05) compared
with those from Tcells of non-vaccinated controls (Figure 8).
Together, these results indicate that the rBsc-PYP-1antigen induced a predominantly Th2-type immune re-
sponse in experimentally vaccinated mice. Considering the
inherent variability of measuring cytokine responses
ex vivo, this assay was repeated in a second trial under the
same experimental conditions. Encouragingly, a similar
cytokine secretion profile was detected in trial II and fur-
ther validated the conclusion proposed above. In compar-
ing these results from trials I and II, no statistically
significant differences were seen (Figure 8).
Discussion
B. schroederi is increasingly recognized as an important
cause of mortality in giant pandas [4,7,8,14], but a pre-
ventative vaccine is currently lacking. As PPases are es-
sential for growth and viability in various organisms
including parasites [21,22], they are attractive targets for
vaccine development against parasitic infections. Specif-
ically, Islam et al. showed in an A. suum mouse infection
model that vaccination with the E. coli-expressed recom-
binant antigen rAsPPase could confer significant host-
protective immunity against parasite challenge [23].
Unfortunately, no information on PPases of B. schroederi
has been reported thus far. In the present study, a new
B. schroederi PPase designated as Bsc-PYP-1 was identi-
fied, cloned and expressed, and its potential as a vaccine
for the control of B. schroederi infection was evaluated
using a mouse challenge model.
Extensive protein database searches revealed that the
deduced amino acid sequence of Bsc-PYP-1 is highly
similar to the A. suum PPase protein AdR44 and moder-
ately similar to PPase homologues from other nematode
species, while failing to share comparable levels of simi-
larity (all values < 20%) with any available PPase proteins
from mammals, including the giant panda, the specific
host of B. schroederi (Figure 1A). These observations
along with the presence of the PPase signature domain
and 13 evolutionarily well-conserved residues, suggest
that Bsc-PYP-1 is a novel nematode-specific PPase with
the likely potential to be developed as a vaccine candi-
date against disease caused by B. schroederi in the giant
panda. Since parasite-specific molecular antigens with
no or low similarity to host proteins are desirable as vac-
cines for parasitic infections because of antibodies in-
duced against them without cross-reaction with host
proteins [46-48]. Similar parasite-specific antigens have
been reported in other nematodes, such as human filar-
ial B. malayi (ALT1, 2 antigens) [49] and swine round-
worm A. suum (14 kDa and 16 kDa antigens) [44,50]. By
immunoblot analysis, rBsc-PYP-1 shows good antigenic-
ity and immunogenicity, which are properties of an ideal
vaccine candidate. Therefore, we further examined
whether rBsc-PYP-1 could provide protection in a B.
schroederi challenge mouse model. Encouragingly, our
data from two separate trials consistently show that
Figure 8 Levels of cytokines produced by splenic T cells from mice subcutaneously vaccinated with rBsc-PYP-1. Splenocytes derived from
trials I and II were stimulated with rBsc-PYP-1 (15 μg/mL) for 72 h in vitro, and concentrations of cytokines (IFN-γ, IL-2, IL-4 and IL-10) in the supernatant
were measured by ELISA. Data are expressed as the mean ± SD for each group of 10 mice. Each sample was examined in triplicate. Asterisks indicate
that the mean value was significantly higher than that of the group immunized with PBS plus FCA or PBS alone (*P < 0.01, **P < 0.001). NS denotes no
statistically significant difference, and error bars indicate SD.
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nization and two boosters at 2-week intervals) with
rBsc-PYP-1 coupled with FCA resulted in protection
against migrating B. schreoderi larvae in the liver and
lung. For both trials I and II, the protection was repre-
sented by significant reductions in the number of
recovered B. schreoderi liver-stage L3 in livers and lar-
vae from lungs after challenge, compared with control
mice (Figure 5 and data not shown). Additionally,
histopathological damage as revealed by the typical
verminous interstitial hepatitis or verminous pneumo-
nia [32] present on the liver and lung of rBsc-PYP-1-
vaccinated mice was also significantly reduced follow-
ing challenge (not shown). Thus, our study indicates
that subcutaneous vaccination of mice with rBsc-PYP-
1/FCA efficiently induced protective immunity against
B. schroederi larval infection.
The immunoprotective effects of rBsc-PYP-1 were fur-
ther confirmed by the high level of protection from
death after parasitic challenge in trial I, with an RPS rate
of up to 80% in the vaccinated group monitored until 80
dpc, compared with controls (Figure 6). It is possiblethat vaccination could alter larval migration from the
liver to lung to other sites that are less lethal than nor-
mal (e.g., diversion from the brain) or inhibit larval
molting and development in a manner that is less patho-
genic. However, such a high RPS observed in the vacci-
nated group appeared to be closely associated with
specific rBsc-PYP-1 humoral and cellular immune re-
sponses. We found that mice immunized with rBsc-PYP-
1 produced high antigen-specific IgG antibody titers
during the experiment. The anti-rBsc-PYP-1 IgG1 levels
increased to a greater extent than that of anti-rBsc-PYP-
1 IgG2a, suggesting that rBsc-PYP-1/FCA vaccination in-
duced a Th2-type immune response. Interestingly, no
antigen-specific IgE response was detected in these mice,
suggesting that rBsc-PYP-1 may be a non-allergenic mol-
ecule, and immune responses to rBsc-PYP-1 were not
mediated by hypersensitivity reactions. IgM responses
were also detected at only a background level until 1
wpc (data not shown). Similar conclusions were drawn
in the repeat experiment (trial II) with different challenge
timepoints. Previous studies have associated parasite-
specific IgG and IgE responses with protective immunity
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have also been reported in experimental pigs or mice im-
munized either by repeated inoculation of A. suum embry-
onated eggs or by parasite crude or recombinant antigens
[50,53]. However, to date, the functional significance of
these two antibody types in protective responses to para-
site infection remains to be defined. It is reasonable to as-
sume that protection, as determined by RPS, in the B.
schroederi infection mouse model may be associated with
high levels of total IgG and both IgG subclasses (IgG1 and
IgG2a). Further investigation using pooled sera from rBsc-
PYP-1/FCA immunized mice for passive immunization
may be used to examine the potential of these antibodies
in blocking B. schroederi larval migration and conse-
quently death in experimentally infected mice. In addition,
the antibody titers of total IgG, IgG1 and IgG2a detected
in the controls (trials I and II) increased slightly after chal-
lenge. This pattern of antibody responses, which is a com-
mon phenomenon in vaccine studies of Baylisascaris spp.
(e.g., Baylisascaris transfuga) where the kinetics of tested
antibodies (including IgG and IgG subclasses) in non-
vaccinated animals characteristically rise after challenge
(H.M. Nie and Y. Fu, personal observations and unpub-
lished data), is putatively attributed to low quantities of
the native antigen present in larvae and the tissue
localization of the endogenous protein in these parasites.
Analysis of antibody responses indicates that rBsc-
PYP-1 plus FCA induced a remarkable Th2-type protect-
ive immunity in vaccinated mice. This conclusion was
supported by subsequent cytokine analyses from two in-
dependent trials, in which the in vitro-stimulated splenic
T cells from rBsc-PYP-1-immunized mice secreted a sig-
nificantly high level of IL-10 and a significantly increased
level of IL-4 (both Th2-type cytokines), while producing
only low levels of the Th1-type cytokines IFN-γ and
IL-2. Since IL-10 is well-known to play an antagonist
role in the production of IFN-γ and IL-2, it was likely
that a high production of IL-10 by CD4+ T cells
suppressed the synthesis of these cytokines by Th1 cells
and CD8+ lymphocytes in mice subcutaneously immu-
nized with rBsc-PYP-1/FCA [54,55]. Additionally, an ele-
vated level of IL-4 (P < 0.01) in immunized mice
apparently did not contribute to IgE production in our
study. By contrast, previous investigations in mice ex-
ploring regulatory and biological functions of parasite-
induced cytokine responses indicated IL-4 as a potent
cytokine with the ability to drive IgE production [56].
Thus, further analysis using IL-4-deficient mice is needed
to clarify this phenomenon. Islam et al. showed that mice
immunized with rAs24 coupled with FCA elicited produc-
tion of a dominant Th2-type cytokine IL-10, together with
IFN-γ but not IL-2, and conferred protection against chal-
lenge as demonstrated by a 58% reduction in recovery and
stunted development of A. suum lung-stage larvae at 7dpc [57]. Hence, we hypothesize that IL-10 may play an
important role in cellular immune responses induced by
rBsc-PYP-1/FCA and even may directly contribute to the
protective immunity against B. schroederi infection in
mice. Interestingly, this hypothesis is supported by a previ-
ous finding that IL-10 is crucial for resistance and survival
of mice infected with Trichuris muris [58].
Currently, effector mechanisms that induce stunted de-
velopment and prevent migration of B. schroederi larvae
after exiting through the host’s gut wall remain poorly
understood. Encouragingly, several studies have verified
that specific IgG antibodies from mice immunized with A.
suum recombinant antigens (rAs24 or rAsPPase) can
penetrate the cuticle of A. suum larvae during the course
of their liver-lung migration and neutralize the corre-
sponding endogenous proteins, thereby interfering with
larval migration and/or growth and development [23,57].
Additional studies have shown that the nematode cuticle
is a dynamic structure with important absorptive, se-
cretory and enzymatic functions and not merely an inert
covering as was once believed [23,59]. These observations
together with our analysis of IgG responses (Figure 7A)
suggest a conspicuous reduction of rBsc-PYP-1-specific
antibody after challenge with infective embryonated eggs,
probably due to similar antibody neutralization of en-
dogenous Bsc-PYP-1 proteins from migrating B. schroederi
larvae. This assumption may be tested in future in vitro
inhibition or toxicity studies of B. schroederi larvae using
anti-rBsc-PYP-1 IgG. It should be noted that the pro-
tective responses to rBsc-PYP-1 against intestinal adult
stage worms were not examined in the present study. In-
deed, immune responses against tissue-dwelling or tissue-
migratory helminths can be different from those against
gastrointestinal parasites [60].
Nematode parasites (including B. schroederi) are mul-
ticellular eukaryotes with complex life cycle stages, and
the adults possess a full complement of immune evasion
strategies [61]. Therefore, finding a specific immune
mechanism that would effectively decrease worm burden
is extremely difficult, and protection often involves both
humoral and cell-mediated responses [62,63]. In the
present study, immunization with rBsc-PYP-1/FCA in-
duced strong Th2-biased humoral and cellular immune
responses and conferred protection against B. schroederi
challenge, as characterized by significant (P < 0.001)
levels of antibodies (e.g., IgG and IgG subclasses, IgG1 >
IgG2a) and IL-10 cytokine (Figure 7 and Figure 8), as
well as significant (P < 0.001) reductions (69.2% and
71.15%) in larval recovery (Figure 5) compared with both
controls. These results, to a certain extent, implied the
potential importance of a rBsc-PYP-1-induced Th2-
mediated immune mechanism in fighting B. schroederi
infection. This current study coupled with the existing
evidence from other gastrointestinal nematode infections
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once again that a nematode-specific Th2 response is
essential for host parasite clearance during infection.
Certainly, more studies should be performed to
reinforce or renew this conclusion. Furthermore, the
percentage of reduction in larval load caused by Bsc-
PYP-1 in our study (69.2–71.15%) was comparable or
slightly higher than those previously reported with B.
schroederi-specific antigens: Bs-Ag1 (69.2%) [26], Bs-
Ag2 (63.66%) [12] and Bs-Ag3 (62.91%) [13]. To a cer-
tain extent, these results suggest that under the same
route and dose in the same adjuvant, Bsc-PYP-1 may
more effectively confer protective immunity against
migrating larvae of B. schroederi in the host, the giant
panda, compared to the three other proteins. Future
clinical vaccine examinations simultaneously testing
these four B. schroederi-derived antigens in pandas
would confirm this assertion. Of course, the vac-
cination protocol for rBsc-PYP-1, as a new candidate
antigen screened from the parasite B. schroederi, will
require further optimization by evaluating different ad-
juvants and administration routes in order to enhance
immune responses.
In summary, we identified and characterized a new
B. schroederi protective antigen commonly expressed
in all life-cycle stages of this parasite as a PPase (Bsc-
PYP-1). Our results demonstrate that subcutaneous
vaccination of mice with E. coli-expressed rBsc-PYP-1,
coupled with FCA, resulted in a remarkable Th2-type
protective immunity against B. schroederi challenge,
and the protection was evident by the significant re-
duction of parasitic load and the high survival rate in
vaccinated mice. These findings provide insight into
rBsc-PYP-1-induced mechanisms that trigger Th2-type
immune responses, which may be important in host-
protective immunity against B. schroederi larvae in-
fection, and they should contribute to further deve-
lopment of Bsc-PYP-1 as a candidate vaccine against
ascariasis, including baylisascariasis.
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